The year ahead for new potential launches

While oncology therapies are just scratching the surface of combatting different types of cancers, neurology is attracting investors and advances in innovative drugs are being made for rare blood disorders.

In this PM360 article, EY-Parthenon Managing Director Alex Jung, Vice President Joe Zaccaria and Brook Chernet, a consultant in the life sciences sector, explore the year ahead for next-generation innovative drugs for three high-unmet-need indications: oncology, neurology, and rare blood disorders.

View the full article here.